Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib in CML-CP with Persistent Disease (ENESTcmr)
NCT00760877Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jun 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00760877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760877.